TiCARos is a clinical-stage biopharmaceutical company focused on transforming cancer treatment through CAR-T cell therapies. Our innovative approach leverages three proprietary technologies—CLIP (CLamping-based Immunological Potentiation), Converter, and Switchable CAR—each designed to overcome the limitations of existing therapies and address critical unmet needs in oncology. The CLIP technology enhances the immunological synapse for more effective targeting and longer engagements with cancer cells. Converter technology amplifies T-cell activation to improve therapeutic potency and durability. Switchable CAR technology allows precise control of CAR-T cell activity, providing a safer and more adaptable treatment option.